Bayer broke ground in May of 2019 on the $150 million Cell Culture Technology Center in Berkeley, Calif. The 40,000-sf. biopharmaceutical manufacturing facility will produce advanced therapeutics for the treatment of cancer and other diseases, enabling the company to expand its biologics development and launch capabilities. Fluor Corporation is providing a single point of responsibility for engineering, procurement, construction management, commissioning, qualification, validation, and integration of the project. Modular construction solutions will be leveraged in the delivery of the facility, which will feature a reconfigurable plant layout that incorporates GE Healthcare's FlexFactory™ Single Use Technology (SUT) platform. Clinical production is expected to begin in late 2021.